Glecaprevir/Pibrentasvir for the Treatment of PTSD

Part of paid clinical trials in White River Junction, Vermont.

Sponsor
White River Junction Veterans Affairs Medical Center
Study ID
NCT05446857
Phase
PHASE2/PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Glecaprevir / Pibrentasvir Pill — DRUG
    Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.

Study Details

An open-label pilot study to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).

Key Dates

Start date
Apr 1, 2023
Status verified
Aug 2024
Primary completion
Apr 15, 2024
Completion
Apr 15, 2024

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Active Drug
    All enrolled participants will receive Glecaprevir/Pibrentasvir

Primary Outcome Measure

Clinical Administered Post-Traumatic Stress Disorder Scale version 5 (CAPS-5) [ Time Frame: Change from Baseline CAPS score at 8 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
White River Junction VAMCWhite River JunctionVermont05009-

Find similar trials in White River Junction, VT

By condition
PTSD (post-traumatic stress disorder)
By specialty
PsychiatryMental healthBehavioral health
By research site
White River Junction VAMC· White River Junction, VT

Related Studies